Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data01:16

Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data

Statistical inference techniques, paramount in hypothesis testing, differentiate into two broad categories: parametric and nonparametric statistics.
Parametric statistics, as the name suggests, assumes that data follow a specific distribution, often a normal distribution. This assumption enables robust hypothesis testing and estimation. Parametric methods, like the Student's t-test or Goodness-of-fit test, are frequently employed in biostatistics due to their robustness. For instance, comparing...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to "Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose" [Vaccine 43 (2025) 126469].

Vaccine·2026
Same author

A Phase 4 Trial to Describe the Immunogenicity, Safety, and Tolerability of MenB-fHbp in Participants > 10 Years of Age With Asplenia or Complement Deficiency.

American journal of hematology·2026
Same author

Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β-Directed Therapies and Other Labeling Updates.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Ampullary Gastrointestinal Stromal Tumor (GIST) - A Rare Culprit for Transient Biliary Obstruction.

Digestive diseases and sciences·2025
Same author

The Herald Bleed-A Fortunate Endoscopic Diagnosis of an Aorto-Duodenal Fistula Secondary to a Mycotic Aortic Aneurysm With Abscess Formation.

Clinical case reports·2025
Same author

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.

Human vaccines & immunotherapeutics·2025

Related Experiment Video

Updated: Jul 16, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.

H M James Hung1, Sue-Jane Wang, Robert O'Neill

  • 1Division of Biometrics I, Office of Biostatistics, OTS/CDER, FDA, Silver Spring, MD 20993-0002, USA. hsienming.hung@fda.hhs.gov

Journal of Biopharmaceutical Statistics
|March 17, 2007
PubMed
Summary

Noninferiority trials without placebo arms need indirect statistical inference. Controlling across-trial Type I error rates is crucial for managing statistical risks in these complex treatment comparisons.

More Related Videos

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Related Experiment Videos

Last Updated: Jul 16, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacoeconomics

Background:

  • Noninferiority trials often lack placebo arms, necessitating indirect statistical inference.
  • Assessing test treatments requires comparing them to active controls and using meta-analyses of historical placebo data.
  • Traditional frequentist Type I error rates are insufficient for indirect inference risks.

Purpose of the Study:

  • To highlight the necessity of considering across-trial Type I error rates in noninferiority trials.
  • To emphasize the importance of controlling statistical risks associated with indirect inference.
  • To inform the definition of noninferiority margins considering multiple error rates.

Main Methods:

  • Direct comparison of test treatment versus active control within the noninferiority trial.
  • Meta-analysis of historical studies to estimate active control effect versus placebo.
  • Evaluation of Type I error rates, including within-trial and across-trial perspectives.

Main Results:

  • Standard within-trial Type I error rates do not adequately assess indirect inference risks.
  • Across-trial Type I error rates must be controlled to manage statistical risks.
  • Methods controlling only across-trial error rates have limited practical utility.

Conclusions:

  • Accurate assessment of noninferiority trials without placebo arms requires considering both within-trial and across-trial Type I error rates.
  • Effective control of statistical risks in indirect inference is paramount.
  • Defining appropriate noninferiority margins depends on a comprehensive understanding of error rates.